C3N-03882
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 68.92265572
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.550
- G2M_CHECKPOINT+0.490
- MYC_TARGETS_V1+0.490
- MYC_TARGETS_V2+0.490
- OXIDATIVE_PHOSPHORYLATION+0.430
- MTORC1_SIGNALING+0.390
- CHOLESTEROL_HOMEOSTASIS+0.310
- UNFOLDED_PROTEIN_RESPONSE+0.300
- SPERMATOGENESIS+0.260
- FATTY_ACID_METABOLISM+0.250
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.590
- ALLOGRAFT_REJECTION-0.500
- IL6_JAK_STAT3_SIGNALING-0.470
- ANGIOGENESIS-0.440
- COAGULATION-0.430
- KRAS_SIGNALING_UP-0.430
- IL2_STAT5_SIGNALING-0.400
- HEDGEHOG_SIGNALING-0.390
- APICAL_JUNCTION-0.370
- TGF_BETA_SIGNALING-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518395 | — | E | 0.926 |
| 2 | a8ce7460-8ccd-4638-a854-55c4068af6ec | — | — | 0.901 |
| 3 | TCGA-58-A46K-01A-11R-A24H-07 | — | cohortSQ2 | 0.901 |
| 4 | TCGA-77-8143-01A-11R-2247-07 | — | cohortSQ1 | 0.900 |
| 5 | f354d13d-89ec-4ed6-821d-df3ab230fc91 | — | — | 0.899 |
| 6 | 9f6a2480-748d-414b-be0b-36be34c24037 | — | — | 0.895 |
| 7 | SRR35579808 | — | C | 0.889 |
| 8 | TCGA-4Z-AA80-01A-11R-A39I-07 | — | — | 0.888 |
| 9 | TCGA-60-2719-01A-01R-0851-07 | — | cohortSQ1 | 0.886 |
| 10 | 96a00cc6-3880-4f03-a08d-73d284787971 | — | — | 0.885 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.490 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.490 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.430 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.390 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.310 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.260 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.190 | Inavolisib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.140 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.110 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.090 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.060 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.040 | Inavolisib | — uncovered |